Synergistic enhancement of antitumor immunity with adoptively transferred tumor-specific CD4+ and CD8+ T cells and intratumoral lymphotactin transgene expression - PubMed (original) (raw)
. 2002 Apr 1;62(7):2043-51.
Affiliations
- PMID: 11929823
Synergistic enhancement of antitumor immunity with adoptively transferred tumor-specific CD4+ and CD8+ T cells and intratumoral lymphotactin transgene expression
Hui Huang et al. Cancer Res. 2002.
Abstract
The lack of efficient T-cell infiltration of tumors is a major obstacle to successful adoptive T-cell therapy. We have shown that transplanted SP2/0 myeloma tumors that have been engineered to express lymphotactin (Lptn) invariably regress under the influence of infiltrating XCR1+T cells and neutrophils. Herein, we characterize these T cells and investigate their therapeutic efficacy, either alone or with Lptn gene therapy. After stimulation with SP2/0 cells, these T cells were CD25+FasL+L-selectin-, expressed XCR-1, and were chemoattracted by Lptn in vitro. They comprised 66% CD4+ Th1 and 33% CD8+ Tc1 cells, both of which expressed significant amounts of IFN-gamma, perforin, and tumor necrosis factor-alpha, but not interleukin-4. The CD4+ Th1 and CD8+ Tc1 cells, which were inhibited and stimulated, respectively, for proliferation with Lptn signaling, displayed 38 and 84% specific killing, respectively, for Ia(d)/H-2K(d)-expressing SP2/0 tumor cells (E:T ratio, 100). In vivo, combined intratumoral Lptn gene transfer and adoptive immunotherapy with these CD4+ and CD8+ T cells eradicated well-established SP2/0 tumors in six of eight mice, and dramatically slowed tumor growth in the other two mice. Cell tracking using labeled T cells confirmed that these cells infiltrated better into the Lptn-expressing tumors than non-Lptn-expressing ones. Control or Lptn adenoviral treatments by themselves did not alter the lethal outcome for tumor-bearing mice, nor did T-cell therapy by itself, although the latter two treatments did slow its time frame. Combined Lptn gene transfer and adoptive CD4+ or CD8+ cell transfers were not nearly as efficacious as the combined Lptn gene and unfractionated T-cell transfers. Taken together, our data provide solid evidence of a potent synergy between adoptive CD4+ and CD8+ T-cell therapy and Lptn gene transfer into tumor tissues, which culminated in the eradication of well-established tumor masses.
Similar articles
- Combined CD4+ Th1 effect and lymphotactin transgene expression enhance CD8+ Tc1 tumor localization and therapy.
Huang H, Bi XG, Yuan JY, Xu SL, Guo XL, Xiang J. Huang H, et al. Gene Ther. 2005 Jun;12(12):999-1010. doi: 10.1038/sj.gt.3302486. Gene Ther. 2005. PMID: 15789061 - Is secretion of tumour-specific antigen important for cancer eradication by CD4(+) T cells?--Implications for cancer immunotherapy by adoptive T cell transfer.
Corthay A, Lorvik KB, Bogen B. Corthay A, et al. Scand J Immunol. 2011 Jun;73(6):527-30. doi: 10.1111/j.1365-3083.2011.02558.x. Scand J Immunol. 2011. PMID: 21388431 Review. - Chemotactic cytokines and inflammation. Biological properties of the lymphocyte and monocyte chemotactic factors ELCF, MCAF and IL-8.
Zachariae CO. Zachariae CO. Acta Derm Venereol Suppl (Stockh). 1993;181:1-37. Acta Derm Venereol Suppl (Stockh). 1993. PMID: 7901957 Review.
Cited by
- Development of a Prognostic Model for Ovarian Cancer Patients Based on Novel Immune Microenvironment Related Genes.
Wang W, Wu Q, Wang Z, Ren S, Shen H, Shi W, Xu Y. Wang W, et al. Front Oncol. 2021 Mar 31;11:647273. doi: 10.3389/fonc.2021.647273. eCollection 2021. Front Oncol. 2021. PMID: 33869044 Free PMC article. - Decitabine treatment sensitizes tumor cells to T-cell-mediated cytotoxicity in patients with myelodysplastic syndromes.
Zhang Z, He Q, Tao Y, Guo J, Xu F, Wu LY, Zhao YS, Wu D, Zhou LY, Su JY, Song LX, Xiao C, Li X, Chang CK. Zhang Z, et al. Am J Transl Res. 2017 Feb 15;9(2):454-465. eCollection 2017. Am J Transl Res. 2017. PMID: 28337274 Free PMC article. - Programmed cell death 2 functions as a tumor suppressor in osteosarcoma.
Yang Y, Jin Y, Du W. Yang Y, et al. Int J Clin Exp Pathol. 2015 Sep 1;8(9):10894-900. eCollection 2015. Int J Clin Exp Pathol. 2015. PMID: 26617804 Free PMC article. - Decitabine facilitates immune recognition of sarcoma cells by upregulating CT antigens, MHC molecules, and ICAM-1.
Krishnadas DK, Bao L, Bai F, Chencheri SC, Lucas K. Krishnadas DK, et al. Tumour Biol. 2014 Jun;35(6):5753-62. doi: 10.1007/s13277-014-1764-9. Epub 2014 Mar 2. Tumour Biol. 2014. PMID: 24584817 - Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy.
Devaud C, John LB, Westwood JA, Darcy PK, Kershaw MH. Devaud C, et al. Oncoimmunology. 2013 Aug 1;2(8):e25961. doi: 10.4161/onci.25961. Epub 2013 Aug 22. Oncoimmunology. 2013. PMID: 24083084 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials